Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase. However, how KRAS mutations promote pancreatic carcinogenesis is not fully understood, and whether oncogenic KRAS is required for the maintenance of pancreatic cancer has not been established. To address these questions, we generated two mouse models of pancreatic tumorigenesis: mice transgenic for inducible KrasG12D, which allows for inducible, pancreas-specific, and reversible expression of the oncogenic KrasG12D, with or without inactivation of one allele of the tumor suppressor gene p53. Here, we report that, early in tumorigenesis, induction of oncogenic KrasG12D reversibly altered normal epithelial differentiation following tissue damage, leading to precancerous lesions. Inactivation of KrasG12D in established precursor lesions and during progression to cancer led to regression of the lesions, indicating that KrasG12D was required for tumor cell survival. Strikingly, during all stages of carcinogenesis, KrasG12D upregulated Hedgehog signaling, inflammatory pathways, and several pathways known to mediate paracrine interactions between epithelial cells and their surrounding microenvironment, thus promoting formation and maintenance of the fibroinflammatory stroma that plays a pivotal role in pancreatic cancer. Our data establish that epithelial KrasG12D influences multiple cell types to drive pancreatic tumorigenesis and is essential for tumor maintenance. They also strongly support the notion that inhibiting KrasG12D, or its downstream effectors, could provide a new approach for the treatment of pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [7]
In the citing paper
“Extinguishing the expression of mutant Kras in the pancreas led to rapid tumor regression, thus demonstrating a critical role of Kras in tumor maintenance (73, 78).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [78]
In the citing paper
“Withdrawal of oncogenic Kras resulted in regression of invasive neoplasia, including regression of metastatic disease63–65.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [63]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Research works printed but not linked: 2
- Klimstra, 1994, Am J Pathol., 145, 1547
- Caldwell, Oncogene.
Cited by
Items 301–400 of 769
Challenges in Ras therapeutics in pancreatic cancer
Choi, M., Bien, H., Mofunanya, A., & Powers, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.015 · Cited by 43
Pal, A., Dziubinski, M., Di Magliano, M. P., Simeone, D. M., Owens, S., Thomas, D., Peterson, L., Potu, H., Talpaz, M., & Donato, N. J. (2018) · Neoplasia · doi:10.1016/j.neo.2017.11.007 · Cited by 39
“In vivomouse models have established the role of oncogenic Kras in the initiation of pancreatic cancer in mice [9,10], while recent reports outline the importance of mutated Kras in pancreatic cancer maintenance [11].”
BackgroundInfluentialAndersen, H. B., Ialchina, R., Pedersen, S. F., & Czaplińska, D. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10004-4 · Cited by 50
Metabolic Features of Cancer Treatment Resistance
Viale, A., & Draetta, G. F. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42118-6_6 · Cited by 39
Ferino, A., Miglietta, G., Picco, R., Vogel, S., Wengel, J., & Xodo, L. E. (2018) · RNA Biology · doi:10.1080/15476286.2018.1526536 · Cited by 38
ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer
Purohit, V., Wang, L., Yang, H., Li, J., Ney, G. M., Gumkowski, E. R., Vaidya, A. J., Wang, A., Bhardwaj, A., Zhao, E., et al. (2021) · Genes & Development · doi:10.1101/gad.344184.120 · Cited by 40
“Conventional chemotherapy often elevates ROS to induce cell death in cancer cells (Kong et al. 2000; Conklin 2004; Pelicano et al. 2004; Mizutani et al. 2005; Wang et al. 2013; Li et al. 2016).”
Tanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023) · Cancers · doi:10.3390/cancers15030724 · Cited by 46
“SHH signaling hyperactivation is driven by activating mutations in KRAS, which is observed in the large majority of PDAC patients [103,104].”
BackgroundTargeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine
Li, B., Zhang, Q., Castaneda, C. N., & Cook, S. M. (2024) · Biomedicines · doi:10.3390/biomedicines12102175 · Cited by 45
“Murine models have convincingly demonstrated that oncogenic KRAS is crucial for both the formation of these precursors and the initiation and maintenance of invasive pancreatic cancers [15].”
BackgroundMcDaid, W. J., Wilson, L., Adderley, H., Martinez-Lopez, A., Baker, M. J., Searle, J., GINN, L. H., Budden, T., Aldea, M. D., Marinello, A., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02157-x · Cited by 50
Pinho, A. V., Mawson, A., Gill, A. J., Arshi, M., Warmerdam, M., Giry-Laterrière, M., Eling, N., Lie, T., Kuster, E., Camargo, S. M. R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11013 · Cited by 40
“We note that SIRT1 was reported to deacetylate KRAS thereby promoting its downstream signaling [39].”
BackgroundInfluentialMutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma
Schofield, H. K., Zeller, J., Espinoza, C. E., Halbrook, C. J., Vecchio, A. D., Magnuson, B., Fabo, T., Daylan, A. E. C., Kovalenko, I., Lee, H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97422 · Cited by 43
“RNA isolation, RT-PCR, and qRT-PCR were performed as previously described (45).”
BackgroundMethodInfluentialSelf-citationWang, K., Baldwin, G. S., Nikfarjam, M., & He, H. Z. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i33.3709 · Cited by 37
Prevention and Reversion of Pancreatic Tumorigenesis through a Differentiation-Based Mechanism
Krah, N. M., Narayanan, S. M., Yugawa, D. E., Straley, J. A., Wright, C. V. E., MacDonald, R. J., & Murtaugh, L. C. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.07.012 · Cited by 46
Giannis, D., Moris, D., & Barbas, A. S. (2021) · Cancers · doi:10.3390/cancers13051071 · Cited by 41
Drosten, M., Guerra, C. E., & Barbacid, M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031542 · Cited by 43
“Addition of a p53 null (Collins et al. 2012) or floxed (Ying et al.”
BackgroundANGPTL4 accelerates KRASG12D-Induced acinar to ductal metaplasia and pancreatic carcinogenesis
YAN, H. H., Jung, K. H., Lee, J. E., Son, M. K., Fang, Z., Park, J. H., Kim, S., Kim, J., Lim, J. H., & Hong, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.036 · Cited by 35
Cancer-Associated Fibroblast Diversity Shapes Tumor Metabolism in Pancreatic Cancer
Peiffer, R., Boumahd, Y., Gullo, C., Crake, R., Letellier, E., Bellahcène, A., & Peulen, O. (2022) · Cancers · doi:10.3390/cancers15010061 · Cited by 38
“However, the stromal expansion of CAFs has been associated with KRAS mutations in pancreatic cancer cells [6].”
Vasseur, R., Skrypek, N., Duchêne, B., Renaud, F., Martínez‐Maqueda, D., Vincent, A., Porchet, N., SEUNINGEN, I. V., & Jonckheere, N. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.10.014 · Cited by 43
Lin, W.-C., Rajbhandari, N., & Wagner, K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3437 · Cited by 39
“This notion is clearly supported by the fact that cancer cells also remained dormant following the ligand-mediated downregulation of mutant Kras in PDAC (26, 28).”
Pitarresi, J. R., Liu, X., Sharma, S. M., Cuitiño, M. C., Kladney, R. D., Mace, T. A., Donohue, S., Nayak, S. G., Qu, C., Lee, J., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.07.006 · Cited by 44
“Neoplasia (2016) 18, 541–552”
Plasticity of differentiated cells in wound repair and tumorigenesis, part I: stomach and pancreas
Burclaff, J., & Mills, J. C. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033373 · Cited by 42
Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers
Hui, D. H. F., Tam, K. J., Jiao, I. Z. F., & Ong, C. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030774 · Cited by 40
“KRAS plays roles in both the initiation and maintenance of pancreatic adenocarcinoma by altering metabolic pathways such as increasing glucose uptake and autophagy [97,98].”
BackgroundJia, X., Lv, M., Fei, Y., Dong, Q., Wang, H., Liu, Q., Li, D., Wang, J., & Wang, E. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121404 · Cited by 36
Pathogenesis of Pancreatic Cancer: Lessons from Animal Models
Murtaugh, L. C. (2013) · Toxicologic Pathology · doi:10.1177/0192623313508250 · Cited by 45
“And most important, when PDAC is induced by Tp53 deletion in iKras mice, doxycycline withdrawal causes regression of both local and metastatic cancer (Collins et al. 2012; Ying et al. 2012).”
BackgroundInfluentialFang, B. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv090 · Cited by 41
“The same results were observed in lung tumors [88] and pancreatic tumors [89,90] induced by doxycycline-regulated Kras.”
K RAS mutation and epithelial–macrophage interplay in pancreatic neoplastic transformation
Bishehsari, F., Zhang, L., Barlass, U., Preite, N. Z., Turturro, S. B., Najor, M. S., Shetuni, B., Zayas, J. P., Mahdavinia, M., Abukhdeir, A. M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31592 · Cited by 37
“Epithelial KRAS activation may also contribute to the inflammatory stroma by upregulating signaling between epithelium and microenvironment.(34,35) Previous studies indicated that KRAS-dependent production of chemoattractants and adhesion molecules could be involved in macrophage recruitment in PDA.”
BackgroundSaloman, J. L., Albers, K. M., Cruz‐Monserrate, Z., Davis, B. M., Edderkaoui, M., Eibl, G., Epouhe, A. Y., Gedeon, J. Y., Gorelick, F. S., Grippo, P. J., et al. (2019) · Pancreas · doi:10.1097/mpa.0000000000001335 · Cited by 38
Cheng, H., Luo, G., Jin, K., Fan, Z., Huang, Q., Gong, Y., Xu, J., Yu, X., & Liu, C. (2020) · Cancer Medicine · doi:10.1002/cam4.2895 · Cited by 41
Critical role of oncogenic KRAS in pancreatic cancer (Review)
Liu, J., Ji, S., Liang, C., Qin, Y., Jin, K., Liang, D., Xu, W., Shi, S., Zhang, B., Liu, L., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5196 · Cited by 37
“In iKRAS mice, inactivation of oncogenic KRAS at any stage of carcinogenesis results in reduced proliferation and smooth muscle actin expression in the stroma (32).”
Glycogen synthase kinase‐3β ablation limits pancreatitis‐induced acinar‐to‐ductal metaplasia
Ding, L., Liou, G., Schmitt, D. M., Störz, P., Zhang, J., & Billadeau, D. D. (2017) · The Journal of Pathology · doi:10.1002/path.4928 · Cited by 40
“Although ADM is a benign lesion and a reversible process [14,15], the presence of mutant KRas ‘locks’ the metaplastic cells in a duct-like state, suggesting that ADM might be an early event that interacts with mutant KRas to promote PDAC development.”
BackgroundLiu, Y., Feng, W., Gu, S., Wang, H., Zhang, Y., Chen, W., Xu, W., Chen, L., Gong, A., & Xu, M. (2019) · Europe PMC (PubMed Central) · Cited by 34
Self-citationWaters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R. Y., Edwards, A. C., Walsh, K. H., Sulahian, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109291 · Cited by 39
“Activating mutations in KRAS are initiating events in pancreatic ductal adenocarcinoma (PDAC) and are required for tumor maintenance (Collins et al., 2012; Ying et al., 2012).”
BackgroundZhang, B., Huang, B., Zhang, X., Li, S., Zhu, J., Chen, X., Song, H., & Shang, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1217654 · Cited by 39
“Additionally, the tumor microenvironment (TME) of patients with PC is complex; hence, the success rate of adjuvant therapy is low compared to surgery (6).”
BackgroundBmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism
Bednar, F., Schofield, H. K., Collins, M. A., Yan, W., Zhang, Y., Shyam, N., Eberle-Singh, J. A., Almada, L. L., Olive, K. P., Bardeesy, N. M., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv058 · Cited by 37
“For this purpose, we induced acute pancreatitis with the cholecystokinin analog caerulein, as described previously (24), starting 3–4 weeks after birth and collected the pancreatic tissues at time points ranging from 24 h to 3 weeks later (n = 3–10 mice/genotype/time point, (scheme in Supplementary Figure 5A is availa…”
InfluentialSelf-citationClinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer
Umemoto, K., Sunakawa, Y., Ueno, M., Furukawa, M., Mizuno, N., Sudo, K., Kawamoto, Y., Kajiwara, T., Ohtsubo, K., Okano, N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02189-y · Cited by 37
“INTRODUCTION Activating KRAS mutations represent an early event during pancreatic tumorigenesis crucial for cancer initiation and progression in about 90% of pancreatic ductal adenocarcinoma (PDAC) [1, 2].”
BackgroundSun, S., Cheng, S., Zhu, Y., Zhang, P., Liu, N., Xu, T., Sun, C., & Lv, Y. (2016) · Gene · doi:10.1016/j.gene.2016.03.020 · Cited by 46
Cogoi, S., Jakobsen, U., Pedersen, E. B., Vogel, S., & Xodo, L. E. (2016) · Scientific Reports · doi:10.1038/srep38468 · Cited by 33
Zhuang, R., Li, S., Li, Q., Guo, X., Shen, F., Sun, H., & Liu, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182562 · Cited by 33
Myeloid Cell-Derived HB-EGF Drives Tissue Recovery After Pancreatitis
Wen, H., Gao, S., Wang, Y., Ray, M., Magnuson, M. A., Wright, C. V. E., di Magliano, M. P., Frankel, T. L., & Crawford, H. C. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.05.006 · Cited by 37
“However, if the inflamed microenvironment also leads to oncogenic mutation in KRAS in the epithelium, stimulation of EGFR/MEK signaling also will promote tumorigenesis.(9,29,56) Our results emphasize that targeting the complex activities of pancreas disease-associated macrophages demands cautious scrutiny.”
BackgroundInhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-07967-6 · Cited by 34
Dicer Regulates Differentiation and Viability during Mouse Pancreatic Cancer Initiation
Morris, J. P., Greer, R. L., Russ, H. A., von Figura, G., Kim, G., Busch, A., Lee, J., Hertel, K. J., Kim, S. K., McManus, M. T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095486 · Cited by 33
“Mouse models have revealed that oncogenic Kras can act as a ‘‘master regulator’’ of PDA development, establishing lineages that can give rise to PanINs and PDA and remaining critical for progression[1,2,3].”
BackgroundSilencing Mist1 Gene Expression Is Essential for Recovery from Acute Pancreatitis
Karki, A., Humphrey, S. E., Steele, R. E., Hess, D. A., Taparowsky, E. J., & Konieczny, S. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145724 · Cited by 37
Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer
Shao, Y. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1224 · Cited by 31
Pancreatic cancer models for translational research
Behrens, D., Walther, W., & Fichtner, I. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.013 · Cited by 40
Seed-in-Soil: Pancreatic Cancer Influenced by Tumor Microenvironment
Lin, H.-J. L., & Lin, J. (2017) · Cancers · doi:10.3390/cancers9070093 · Cited by 33
“KrasG12D is required for both the initiation and maintenance processes of pancreatic cancer in mouse models, and was shown to be the most common oncogenic KRAS mutation presented in more than 90% of human PDAC, leading to a dominant and constitutively active form of GTPase [69,70].”
BackgroundWang, L., Zhao, L., Guo, W., Saur, D., Seidler, B., Wang, J., Wang, C., & Qi, T. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26847 · Cited by 34
PD2/Paf1 depletion in pancreatic acinar cells promotes acinar-to-ductal metaplasia
Dey, P., Rachagani, S., Vaz, A. P., Ponnusamy, M. P., & Batra, S. K. (2014) · Oncotarget · doi:10.18632/oncotarget.2041 · Cited by 31
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer
Cheng, D. K., Oni, T. E., Thalappillil, J. S., Park, Y., Ting, H.-C., Alagesan, B., Prasad, N. V., Addison, K., Rivera, K. D., Pappin, D. J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016904118 · Cited by 30
“Additionally, independent studies have shown that the maintenance of murine PDAC cells require KRAS (12 – 14).”
K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1135131 · Cited by 32
“naling is essential not only for PDAC initiation but also for its progression, maintenance [93,94], and metastatic lesion”
BackgroundCritical role of KRAS mutation in pancreatic ductal adenocarcinoma
Fan, Z., Fan, K., Yan, C., Huang, Q., Gong, Y., Cheng, H., Jin, K., Liu, C., Ni, Q., Yu, X., et al. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.19 · Cited by 34
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 30
“Initial experiments using magnetic resonance imaging to follow individual animals in longitudinal studies, confirmed that elimination of KrasG12D expression resulted in striking tumor regression [88,89].”
BackgroundMethodInfluentialHuman Correlates of Provocative Questions in Pancreatic Pathology
McDonald, O. G., Maitra, A., & Hruban, R. H. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318273f998 · Cited by 32
Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells
Chang, Z., Li, Z., Wang, X., Kang, Y., Yuan, Y., Niu, J., Wang, H., Chatterjee, D., Fleming, J. B., Li, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0032 · Cited by 31
“Clin Cancer Res; 19(3) February 1, 2013 Clinical Cancer Research 556”
BackgroundInfluentialLi, T., Zheng, Y., Sun, H., Zhuang, R., Liu, J., Liu, T., & Cai, W. (2016) · Medical Oncology · doi:10.1007/s12032-016-0777-1 · Cited by 32
Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
Pienkowski, T., Wawrzak-Pienkowska, K., Tankiewicz‐Kwedlo, A., Ciborowski, M., Kurek, K., & Pawlak, D. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07517-z · Cited by 35
“Additionally, germline mutations in genes like BRCA1, BRCA2, PALB2, ATM, and mismatch repair genes (MLH1, MSH2, MSH6) are associated with an increased predisposition to pancreatic cancer [5, 6].”
Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
Smith, C., Zheng, W., Dong, J., Wang, Y., Lai, J., Liu, X., & Yin, F. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i27.3297 · Cited by 31
The renewed battle against RAS-mutant cancers
Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 32
Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze
Olivares, O., & Vasseur, S. (2015) · International Journal of Cancer · doi:10.1002/ijc.29501 · Cited by 29
The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment
Sun, H., Zhang, B., & Li, H. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820920969 · Cited by 31
“Notably, these immunoregulatory factors are expressed in an KRAS-dependent manner.(33) In PDAC, sonic hedgehog expressed by tumor cells, while IL-6 is mainly secreted by inflammatory cells but can be significantly induced by KRAS-mutated cells.”
BackgroundMultifunctional Applications of Engineered Extracellular Vesicles in the Treatment of Cancer
Kugeratski, F. G., McAndrews, K. M., & Kalluri, R. (2021) · Endocrinology · doi:10.1210/endocr/bqaa250 · Cited by 28
Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 35
“A study of the inducible KrasG12D;Trp53-/- PDAC mouse model (84) revealed cancer cell-intrinsic mechanisms enabling bypass of KRAS dependency and tumor recurrence (85).”
BackgroundChen, J., Liu, Z., Wu, Z., Li, W., & Tan, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1132424 · Cited by 41
“Mutated KRAS contributes to the development of the immunosuppressive TME in PC through several avenues, including recruitment of MDSCs and Treg cells (80, 81), maintenance of the fibroinflammatory stroma (82), induction of Th17 cells (83), and upregulation of PD-L1 expression via mRNA stabilization (84).”
BackgroundInvestigating the role of transcription factors of pancreas development in pancreatic cancer
Naqvi, A. A. T., Hasan, G. M., & Hassan, M. I. (2017) · Pancreatology · doi:10.1016/j.pan.2017.12.013 · Cited by 34
Quattrochi, B., Gulvady, A., Driscoll, D. R., Sano, M., Klimstra, D., Turner, C., & Lewis, B. (2017) · OncoTarget · doi:10.18632/oncotarget.16277 · Cited by 32
“In contrast, our studies demonstrate that ectopic mir-17~92 increases MEK/ERK signaling, a feature required for the maintenance of established PanIN lesions [6, 67], suggesting that elevated mir-17~92 levels should enhance pancreatic cancer development.”
ResultSRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma
Song, X., Chen, H., Zhang, C., Yu, Y., Chen, Z., Liang, H., Buren, G. V., McElhany, A. L., Fisher, W. E., Lonard, D. M., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.012 · Cited by 28
“Oncogenic KRAS signaling is essential for initiation, progression and maintenance of PDAC [33, 34].”
BackgroundEscaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Adachi, Y., Kimura, R., Hirade, K., & Ebi, H. (2021) · Cancers · doi:10.3390/cancers13205081 · Cited by 30
“Furthermore, pancreatic tumors became atrophic with rare activation of MAPK signaling [20].”
BackgroundBansod, S., Dodhiawala, P. B., & Lim, K. (2021) · Cancers · doi:10.3390/cancers13215481 · Cited by 31
“In another GEMM in which KRASG12D expression can be reversibly switched on/off by doxycycline treatment, maintenance of neoplastic epithelia, activation of fibroblasts, and infiltration of immune cells require the continual expression of KRASG12D, which upregulates different tumor-intrinsic signaling pathways includin…”
BackgroundKato, K., Kamada, H., Fujimori, T., Aritomo, Y., Ono, M., & Masaki, T. (2012) · Gastroenterology Research and Practice · doi:10.1155/2012/243524 · Cited by 31
“Interestingly, KRAS mutations are frequently detected in the most common precursor lesion to pancreatic cancer, pancreatic intraepithelial neoplasia (PanIN), indicating a potential role for early pancreatic cancer in the disease [4, 5].”
BackgroundPancreatic Cancer: Current Status and Challenges
Muñoz, A. R., Chakravarthy, D., Gong, J., Halff, G. A., Ghosh, R., & Kumar, A. P. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0112-3 · Cited by 30
Mondal, P., Kaur, B., Natesh, J., & Meeran, S. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.04.001 · Cited by 29
New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment
Yan, B., & Liang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415758 · Cited by 28
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Long, S.-A., Amparo, A. M., Goodhart, G., Ahmad, S. A., & Waters, A. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402128 · Cited by 31
Jin, R. U., & Mills, J. C. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000540 · Cited by 27
Wang, H., Wang, X., Xu, L., Lin, Y., Zhang, J., & Cao, H. (2020) · Aging · doi:10.18632/aging.103958 · Cited by 30
Assi, M. N., Achouri, Y., Loriot, A. E., Dauguet, N., Dahou, H., Baldan, J., Libert, M., Fain, J. S., Guerra, C. E., Bouwens, L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2976 · Cited by 28
“Another supporting independent observation comes from Collins and colleagues showing that increased protein expression of oncogenic KRAS in an adult pancreas, from an ectopic promoter, is associated with a significant and rapid development of PanIN and PDAC, without requiring experimental pancreatitis (37).”
BackgroundHusain, K., Villalobos-Ayala, K., Laverde, V., Vazquez, O. A., Miller, B., Kazim, S., Blanck, G., Hibbs, M. L., Krystal, G., Elhussin, I., et al. (2022) · Cancers · doi:10.3390/cancers14153613 · Cited by 26
“The inhibition of PC cell growth by API may be due to the downregulation of PI3K/AKT and MAPK/MEK/ERK pathways as these kinases are down stream of Kras oncogene which is mutated in 90% of patients with PC [79,80].”
BackgroundPolymeric micelles assisted combinatorial therapy: Is it new hope for pancreatic cancer?
Rehman, U., Abourehab, M. A. S., Alexander, A., & Kesharwani, P. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111784 · Cited by 26
The role of pancreatic stellate cells in pancreatic cancer
Erkan, M. (2013) · Pancreatology · doi:10.1016/j.pan.2013.01.008 · Cited by 26
“In a genetically engineered mouse model, when the Kras activity was turned off, the chronic pancreatitis-like changes of the stromawere also reduced, and normal acinar architecture of the gland was regained [17].”
BackgroundInfluentialDosch, J. S., Ziemke, E. K., Shettigar, A., Rehemtulla, A., & Sebolt, J. S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2793 · Cited by 28
“Hematoxylin and eosin (H&E), Periodic Acid Staining (PAS), and Masson's trichrome staining were done with assistance from the lab of Marina Pasca di Magliano and were performed as previously described (28).”
Zeb1 in Stromal Myofibroblasts Promotes Kras -Driven Development of Pancreatic Cancer
Sangrador, I., Molero, X., Campbell, F., Franch‐Expósito, S., Rovira-Rigau, M., Samper, E., Domínguez-Fraile, M., Fillat, C., Castells, A., & Vaquero, E. C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1882 · Cited by 27
Maddipati, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191943 · Cited by 37
“In murine PDAC, silencing of KRAS or MYC expression induces tumor regression and limits metastasis (52, 172).”
van Roey, R., Brabletz, T., Stemmler, M. P., & Armstark, I. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.753456 · Cited by 27
“This suppressed redifferentiation promotes PanIN progression (Morris et al., 2010; Collins et al., 2012).”
Li, S., & Xie, K. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188698 · Cited by 27
BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities
Ciner, A., Jiang, Y., & Hausner, P. F. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0626 · Cited by 26
Energy metabolism and proliferation in pancreatic carcinogenesis
Regel, I., Kong, B., Raulefs, S., Erkan, M., Michalski, C. W., Hartel, M., & Kleeff, J. H. (2012) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-012-0933-9 · Cited by 27
“stages of the disease, a recent study provided evidence that oncogenic Kras signaling is required in all stages of tumorigenesis [50].”
BackgroundHassid, B. G., Lucas, A. L., Salomao, M. A., Weng, C., Liu, F., Khanna, L. G., Kumar, S., Hwang, C., Chabot, J. A., & Frucht, H. (2014) · Pancreas · doi:10.1097/mpa.0000000000000161 · Cited by 29
Klieser, E., Swierczynski, S., Mayr, C., Jäger, T., Schmidt, J., Neureiter, D., Kiesslich, T., & Illig, R. (2016) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v7.i2.199 · Cited by 25
Are Gastric and Esophageal Metaplasia Relatives? The Case for Barrett’s Stemming from SPEM
Jin, R. U., & Mills, J. C. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5150-0 · Cited by 28
PDAC as an immune evasive disease: can 3D model systems aid to tackle this clinical problem?
Narayanan, S., Vicent, S., & Ponz-Sarvisé, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.787249 · Cited by 24
“, 2017), KRAS mutations strongly influence tumor maintenance and metastasis (Collins et al., 2012).”
BackgroundBroderick, C., Mezzadra, R., Sisso, E. M., Mbuga, F., Raghulan, R., Perez, A. C., Kulick, A. R., Jiang, L., Jiang, J., Ho, Y.-J., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1425 · Cited by 32
Harada, A., Matsumoto, S., Yasumizu, Y., Shojima, K., Akama, T., Eguchi, H., & Kikuchi, A. (2021) · eLife · doi:10.7554/elife.66721 · Cited by 27
Mehra, S., Garrido, V. T., Dosch, A. R., Lamichhane, P., Srinivasan, S., Singh, S. P., Zhou, Z., Silva, I. D. C., Joshi, C. G., Ban, Y. J., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0329 · Cited by 26
“Previous studies have shown this resistant phenotypeisreliantononcogenic KRAS mutationstodrivediseaseprogression (8, 9).”
Lanfranca, M. P., Lazarus, J., Shao, X., Nathan, H., di Magliano, M. P., Zou, W., Piert, M., & Frankel, T. L. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.07.015 · Cited by 26
ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis
Wang, L., Yang, H., Zamperone, A., Diolaiti, D., Palmbos, P. L., Abel, E. V., Purohit, V., Dolgalev, I., Rhim, A. D., Ljungman, M. E., et al. (2019) · Genes & Development · doi:10.1101/gad.323303.118 · Cited by 26
“It has been shown previously that continuous expression of oncogenic KRAS is required for PanIN formation and progression and cancer maintenance in the iKras model, allowing inducible and reversible expression of oncogenic KRAS (Collins et al. 2012).”
Advances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 25
Sáenz, J. B., Vargas, N., Cho, C. J., & Mills, J. C. (2022) · JCI Insight · doi:10.1172/jci.insight.153511 · Cited by 25
“…proliferation of metaplastic epithelium serves a reparative, wound-healing function, but in the setting of sustained injury, every reentry into the cell cycle has the potential to enable the accumulation of mutations that can eventually be unmasked when expressed in proliferating cells (62, 63).”
Ferroptosis: A Specific Vulnerability of RAS-Driven Cancers?
Andreani, C., Bartolacci, C., & Scaglioni, P. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.923915 · Cited by 30
“Accordingly, doxycycline (dox)-inducible KM mice have shown that KM is necessary for tumorigenesis and that extinction of KM leads to complete tumor regression (24, 25).”
BackgroundPharmacological inhibition and reversal of pancreatic acinar ductal metaplasia
Silva, L. D., Jiang, J., Perkins, C. M., Atanasova, K. R., Bray, J. K., Bulut, G. B., Azevedo‐Pouly, A. C. P., Campbell‐Thompson, M., Yang, X. T., Hakimjavadi, H., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01165-4 · Cited by 27
PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer
Nimmakayala, R. K., Ogunleye, A. O., Parte, S. C., Kumar, N. K., Raut, P., Varadharaj, V., Perumal, N. K., Nallasamy, P., Rauth, S., Cox, J. L., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05258-x · Cited by 23
“The major pancreatic preprecursor lesions derived from pancreatic acinar cells in response to the Kras mutation are acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) [1].”
BackgroundMasugi, Y., Takamatsu, M., Tanaka, M., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2023) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.323 · Cited by 23
Metadata
- Authors
- Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 639-653
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3266788
- OpenAlex
- W2018159884
- Cited by
- 770
- References
- 66
- Citations by year
- 2026: 40 · 2025: 41 · 2024: 53 · 2023: 63 · 2022: 71 · 2021: 80 · 2020: 51 · 2019: 43 · 2018: 54 · 2017: 69 · 2016: 56 · 2015: 45 · 2014: 52 · 2013: 41 · 2012: 11
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- American College of Surgeons
- Vanderbilt University
- University of Pennsylvania
- University of Michigan
- National Institutes of Health (NIH T32, P30 DK, 5-T32-HD007515)
- National Cancer Institute (R01CA151588, P50CA130810, P50CA13810)
- National Institute of General Medical Sciences (T32GM07315, T32GM007315)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (5-T32-HD007515, T32HD007505)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, KRAS G12D, oncogenic KRAS, pancreatic carcinogenesis, tumor maintenance, p53, precancerous lesions, epithelial differentiation, Hedgehog signaling, inflammation, tumor microenvironment, tumor regression, KRAS inhibition
- MeSH terms
- Animals, Cell Differentiation, Cell Transformation, Neoplastic, Disease Models, Animal, Epithelial Cells, Humans, Mice, Transgenic, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Survival Rate, Proto-Oncogene Proteins p21(ras), Mice, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.